Drugs / CRG003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06178432 | Dec 2023 → Dec 2024 overdue | glycogen storage disease due to acid maltase deficiency, late-onset | Huashan Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRG003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06178432 ↗ |
| Action | Restore | “to stably express active GAA enzyme in the liver on a long-term basis after the injection” NCT06178432 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “CRG003 (BBM-G102) injection is an adeno-associated virus (AAV) gene therapy product” NCT06178432 ↗ |
| Route | Intravenous | “single intravenous infusion” NCT06178432 ↗ |
| Target | GAA | “to stably express active GAA enzyme in the liver” NCT06178432 ↗ |